Literature DB >> 3091596

Nature of the enhancement of lecithin-cholesterol acyltransferase reaction by various apolipoproteins.

H I Nishida, T Nakanishi, E A Yen, H Arai, F T Yen, T Nishida.   

Abstract

The effects of human apolipoproteins on the lecithin-cholesterol acyltransferase reaction were studied by using purified human lecithin-cholesterol acyltransferase and phosphatidylcholine-cholesterol vesicles. When the assay mixtures contained an optimal amount or excess of apo-A-I, the addition of apo-A-II, apo-C-II, apo-C-III1, or apo-C-III2 inhibited the enzymatic reaction. However, at suboptimal apo-A-I concentrations, the addition of low concentrations of these apolipoproteins exhibited activating effects. The relative activating effects were greater at lower apo-A-I levels. Under no circumstance did the combined activating effect of apo-A-I and other apolipoproteins exceed the maximum activating effect observed with the optimal level of apo-A-I alone. Since apo-A-II, apo-C-II, and apo-C-III did not show significant activating effects in the absence of apo-A-I, these apolipoproteins apparently did not act as true activator proteins for the enzymatic reaction. The activation of the enzymatic reaction by apo-A-I alone was shown to be due in part to the enhancement of the enzyme transfer between the substrate particles. The replacement of the transfer-enhancing effect of apo-A-I by apo-A-II, apo-C-II, or apo-C-III appears to be responsible for their apparent activating effects in the presence of suboptimal levels of apo-A-I. These apolipoproteins seemed to coexist with both the enzyme and apo-A-I on the substrate particles under the conditions when they showed the activating effect. However, at the concentrations inhibitory to the enzymatic reaction, these apolipoproteins displaced both the enzyme and apo-A-I from the phosphatidylcholine-cholesterol vesicles.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3091596

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Surface rheology and adsorption kinetics reveal the relative amphiphilicity, interfacial activity, and stability of human exchangeable apolipoproteins.

Authors:  Victor Martin Bolanos-Garcia; Anne Renault; Sylvie Beaufils
Journal:  Biophys J       Date:  2007-11-09       Impact factor: 4.033

Review 2.  The relationship between high density lipoprotein subclass profile and apolipoprotein concentrations.

Authors:  L Tian; M Fu
Journal:  J Endocrinol Invest       Date:  2011-06       Impact factor: 4.256

3.  Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity.

Authors:  Evangelia Zvintzou; Marie Lhomme; Stella Chasapi; Serafoula Filou; Vassilis Theodoropoulos; Eva Xapapadaki; Anatol Kontush; George Spyroulias; Constantinos C Tellis; Alexandros D Tselepis; Caterina Constantinou; Kyriakos E Kypreos
Journal:  J Lipid Res       Date:  2017-07-12       Impact factor: 5.922

4.  Expression of human lecithin-cholesterol acyltransferase in transgenic mice. Effect of human apolipoprotein AI and human apolipoprotein all on plasma lipoprotein cholesterol metabolism.

Authors:  O L Francone; E L Gong; D S Ng; C J Fielding; E M Rubin
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

5.  ApoE and apoC-III-defined HDL subtypes: a descriptive study of their lecithin cholesterol acyl transferase and cholesteryl ester transfer protein content and activity.

Authors:  Mateo Amaya-Montoya; Jairo A Pinzón-Cortés; Lina S Silva-Bermúdez; Daniel Ruiz-Manco; Maria C Pérez-Matos; Mario A Jiménez-Mora; Carlos O Mendivil
Journal:  Lipids Health Dis       Date:  2020-05-25       Impact factor: 3.876

6.  Association between lipids, lipoproteins composition of HDL particles and triglyceride-rich lipoproteins, and LCAT and CETP activity in post-renal transplant patients.

Authors:  Elżbieta Kimak; Jerzy Bylina; Janusz Solski; Magdalena Hałabiś; Iwona Baranowicz-Gąszczyk; Andrzej Książek
Journal:  Cell Biochem Biophys       Date:  2013-11       Impact factor: 2.194

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.